Multifunctional polymersomes loaded with maghemite nanoparticles and grafted with an antibody, directed against human endothelial receptor 2, are developed as novel MRI contrast agents for bone metastasis imaging. Upon administration, in mice bearing orthotopic metastatic breast cancer, MR images show targeting and enhanced retention of antibodylabeled polymersomes at the tumor site.
Breast cancer is the most prevalent cancer and second leading cause of cancer mortality in women. [1] In nearly 50% of primary cancers, and 80% of recurring metastases, this type of cancer preferentially metastasizes to the skeleton, e.g. femur, pelvis, vertebrae and skull [2] , leading to poor vital prognosis. [3] . Due to their body location (profound tissue surrounded by a mineralized bone matrix) and the heterogeneity of pathological tissue, the use of new tools, allowing specific detection of these malignant cells, may result in better treatment outcome and patient survival. High-performance imaging, providing spatial resolution in three dimensions, is required for the detection of small-sized tumors (such as early metastatic stages). In this context, magnetic resonance imaging (MRI) is a good candidate for noninvasive characterization of tumor development in vivo. Widely implemented in clinical practice, MRI provides a sensitive method for the detection of bone marrow metastases. [4] Tumor detection is usually carried out using the natural or gadolinium-enhanced contrast between healthy tissue and tumor tissue, but specifically targeted contrast agents can ensure precise tumor delineation and allow a more accurate diagnostic.
During the past two decades, magnetic nanoparticles and particularly ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) and clusters of the later (generally assembled using organic material and designated as superparamagnetic iron oxides, SPIOs) [5] have been widely investigated as MRI contrast agents owing to their unique characteristics: efficient contrast effects (as negative (T 2 ) contrast agents), biocompatibility, and possible surface functionalization. [5, 6] Recent work has indeed demonstrated the utility of targeting iron oxide particles towards the development of pathology-specific MRI contrast agents. [7, 8, 9, 10] On the other hand, polymersomes, vesicular structures generated by self-assembly of amphiphilic copolymers, are promising drug carriers that can accommodate both hydrophobic and hydrophilic cargo within their membrane and aqueous core, respectively. [11] Recently, several authors have shown that high amounts of USPIOs could be incorporated within these structures with a good control over their morphology and size and, at the same time, superior transverse relaxometric properties (high r 2 values). [12] Our group previously developed such hybrid polymersomes where the embedded USPIOs acted as both MRI contrast agents (with r 2 up to 182 s -1 .mM Fe -1 ) and actuators for magnetic field induced drug release (magnetochemotherapy). [13] Another interesting development of polymersomes in the recent years is their functionalization with targeting molecules (protein, peptide or small molecule). Indeed, targeted polymersomes have been successfully implemented for vascular targeting and receptor-mediated endocytosis [14] , leading to improved drug efficiency, especially with antibodies as ligand [15] .
Here, by means of polymersome surface functionalization using cell specific targeting ligands (antibodies), we demonstrate hybrid polymersomes application as T 2 * MRI contrast agents for specific targeting of a breast cancer bone metastases model. The overexpression of the membrane tyrosine kinase Human Epidermal Growth Factor Receptor-2 (HER2), found in approximately 20% of breast cancers [16] , is associated with a poor prognosis, making this receptor a potential target for guided therapy. Indeed, several examples of successful HER2 targeting have been recently described. [7, 8, 17, 18] [18] Hence, trastuzumab, the first monoclonal humanized antibody targeting HER2, approved by FDA in 1998, and currently applied in the clinical field, [19] was used as ligand to target breast cancer cells in a bone metastasis model.
Polymersomes were prepared from a blend of amphiphilic block copolymers:
poly(trimethylene carbonate)-b-poly(glutamic acid), the same copolymer end-capped with either a maleimide group or fluorescein, and hydrophobically coated USPIOs (30 wt% to polymer). After nanoprecipitation in buffer, maleimide-bearing polymersomes were reacted with thiol-derivatized trastuzumab to obtain the targeted multifunctional polymer vesicles ( Figure 1A , experimental procedures are detailed in Supporting Information).
These multifunctional polymersomes were further tested in a clinically relevant model. A majority of studies focused in large subcutaneous xenograft cancer models [7, 8, 18] , presenting poor relevance in a metastasis detection scenario. Indeed, in some cases, the tumor volume reached 1 cm 3 , representing a significant percentage of the mice body weight. The size of the tumors can influence tumor vascularization and dramatically change its microenvironment, with a drastic impact on the contrast agent overall performances. [20] Recently, a more realistic animal model was presented by Kievit et al. [21] : transgenic mice with intact immune system were used, developing tumors in a natural manner, with metastases appearing in lungs, liver and bone. Unfortunately, due to their small size, bone metastases were not detected by MRI in this study. Here, focusing on a diagnostic clinical scenario, we propose an animal model bearing small tumors (12-15µl), mimicking a relevant metastasis environment. Spontaneous bone metastases, arising from primary breast tumor, are uncommon and this has prompted the wide use of bone tumor models based on local or systemic injection of tumor cells. One of the main disadvantages of the systemic injection resides on the lack of control of the tumor final localization and pathogenesis. [22] In that sense, we developed a bone cancer model by As observed in Figure 1C , naked and antibody-grafted polymersomes presented similar size and zeta potential, consistent with previous reports. [13, 23] Using the previously determined aggregation number, [23] we estimated an average number of antibody per vesicle of 31, corresponding to a grafting efficiency of 86% (Supporting Information). The developed systems relaxivity (r 2 ) was evaluated at 4.7 T (200 MHz operating frequency) and values were found consistent with previous reports using similar USPIOs. [9, 24] The targeting potential of the developed system was first tested in an in vitro setting. After exposure to the polymer vesicles, cells were analyzed by flow cytometry: polymersomes fluorescently labeled and functionalized with trastuzumab showed a clear targeting (six fold increase of the number of FITC positive cells) towards BT-474 cells (HER2 positive) as compared with naked particles (Figure 1D) . Moreover, when cells expressing low levels of HER2 (i.e. MDA-MB-231 breast cancer cell line [25] ) were used, no significant differences were observed for the two formulations tested (Figure 1D) , demonstrating the specificity of the targeting. Interestingly, thanks to the polymersomes high USPIOs content, MRI also evidenced the targeting towards BT-474 cells. Indeed, as observed in Figure 1E , cells incubated with targeted polymersomes and embedded in a transparent gel appeared with a negative contrast (T 2 * effect in gradient echo images), accounting for the uptake of polymersomes, whereas cells incubated with naked polymersomes showed no change in contrast as compared to control cells.
MRI was also used to perform real time whole body biodistribution [26] (4.7 Tesla; Figure 2A ).
Figure 2B
presents signal-to-noise ratio (SNR) as a function of time (pre-contrast minus postcontrast values, ∆SNR) for 3 tissues (i.e. blood, liver and muscle). Despite a quick uptake by the liver, blood data show that the injected polymersomes persist in circulation for at least 20 min (Figure 2A and 2B) . Similar results where found after naked polymersomes administration (data not shown) and for other nanoparticles with similar sizes. [27] Interestingly, MRI signal analysis of the tumor tissue showed that naked polymersomes are less retained than the targeted ones ( Figure 2E) . Additionally, superior contrast was observed in the tumor bone, when compared with the contralateral femur tissue (Figure 2C, D) , attesting the targeting specificity in a clinically relevant in vivo scenario. This behavior can be explained by the small size of the internal lesions without fully developed vascularization in the bone. Indeed, larger tumors generally contain leaky vasculature associated with insufficient lymph drainage that is correlated with an enhanced permeability and retention (EPR) effect of nanoparticles also referred to as passive targeting. [28] In the case of smaller tumor structures, where angiogenesis might be less influenced by anoxic conditions, this EPR effect is very limited. In such a context, the development of nanoparticles with an "active targeting" (grafting of a specific ligand) is necessary to reach the tumor and maintain a high concentration at the tumor site. As a result, this was only when targeted polymersomes were used that a more persistent T 2 * contrast effect was observed at the tumor site, associated with an increased residence time of the contrast agent.
To our knowledge, this is the first report of USPIO-loaded polymeric vesicles used as MRI contrast agent and able to target cancer cells in vivo, in a relevant animal model for bone metastasis. This approach opens new avenues for the development of more powerful diagnostic tools developed on the basis of higher specificity. Indeed, to avoid any loss in binding affinity, only a limited number of contrast agent structures can be grafted onto one antibody. For common MRI contrast agents such as gadolinium complexes, the concentration of contrast agent at the targeted site achieved with such labeled antibodies is usually insufficient to generate detectable MRI contrast. [29] In the case of magnetic polymersomes however, the high relaxivity provided by the USPIOs clustering effect associated with the binding of several antibodies per particle potentiate the efficiency as targeted MRI contrast agent.
Thanks to the versatility of the polymersome structure, other -or complex mixtures oftargeting moieties can be used in order to assess other tissues or pathological situations, broadening their application as diagnostic tools. Moreover, as previously reported by our group, the developed systems are able to load high amounts of drug and USPIOs (i.e. 12%
(w/w) of doxorubicin while also encapsulating 50% (w/w) of USPIOs). [13, 23] In comparison with other reported vesicular systems, where a doxorubicin loading of only 3.3% (w/w) was reached, [7] these polymersomes open new perspectives for the development of targeted tools for a dual diagnostic and therapy purpose.
Experimental Section
A detailed description of experimental procedures can be found in the supporting information.
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Supporting Information is available online from Wiley InterScience or from the author.
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Experimental Section
Polymersomes formulation and characterization:
Poly(trimethylene carbonate)-b-poly(l-glutamic acid) (PTMC-b-PGA) copolymer was synthesized by ring-opening polymerization as previously described [30] . In order to form thiol-reactive vesicles, based on PTMC-b-PGA copolymer, a triblock formation strategy was followed. In that sense a bifunctional (i.e. N-Hydroxysuccinimide and maleimide) 2kDa PEG (JenkemUSA, China) was grafted to the diblock copolymer. Briefly, PTMC 26 For fluorescent labeling, PTMC-b-PGA was modified in bulk using FITC. Briefly, copolymer (250 mg) was dissolved in anhydrous DMSO (5 mL) and DIPEA (100µL; 1 eq. per acid function) was added. After 5 min stirring, FITC (18 mg; 1 eq.) was added and the mixture was stirred overnight at room temperature. The resulting product was dialyzed against ultrapure water for three days and freeze dried.
The strategy of the antibody grafting to the polymersome surface consisted in the reaction of the thiolated protein to the active maleimide groups in the polymersome surface. In that sense the antibody was thiolated in a controlled fashion, as follows. Trastuzumab (purified from Herceptin®, Roche) was dispersed in 50 mM phosphate buffer pH 8.0 (at 5 mg/mL) and a 50fold molar excess of 2-iminothiolane (Sigma) was added and left to react for 2 hrs at room temperature, as described elsewhere [31] . Unreacted 2-iminothiolane was removed using ultrafiltration (50 kDa, Spinx-UF20, Corning) with 50 mM phosphate buffer pH 6.5. The antibody concentration was determined by OD280 (corrected to 1 mg/mL), snap frozen and kept at -20ºC until further use. The number of thiols per antibody was determined using
Ellman's assay [32] . The influence of thiolation in the antibody dispersion stability was followed by DLS, with no aggregation being observed (Figure S1, A) . Tratuzumab antibody presented a hydrodynamic diameter of 12.3±1.1 and 12.9±0.4 nm, with a polydispersity index of 0.18 and 0.17, for native and thiolated, respectively.
Superparamagnetic iron oxide nanoparticles (USPIOs; γ-Fe 2 O 3 ) were synthesized as previously described [33] , sorted according to their size by fractionated phase separations and characterized along the sorting process by vibrating sample magnetometry (VSM) and on the final sample by scattering techniques (SLS, DLS and SANS). Then they were grafted with the anionic surfactant Beycostat NB09 (CECA, Arkema group, France) as described elsewhere [34] , in order to allow their inclusion in the polymersome hydrophobic reservoir.
Polymersomes were obtained by the nanoprecipitation method (solvent assisted dispersion).
Briefly Nanoparticle were purified via ultrafiltration (3 x) using a filter cut off of 100 kDa, with phosphate buffer, 50 mM, pH 6.5. Total mass of the dispersion was determined using gravimetry and total iron content was assessed as described elsewhere [35] . (estimated using the previously determined aggregation number [36] ). The grafting efficiency was expressed as the percentage of grafted antibody (quantified after final step of purification by means of the BCA assay) in relation to the total amount initially reacted with polymersomes. In view of comproving the efficient antibody grafting a small amount of the nanoparticle dispersion, before and after the final step of purification, where loaded in a 7% SDS PAGE gel (lacking reducing agents). Free trastuzumab was run alongside grafted nanoparticles. As observed in figure S1, B , when the antibody is grafted to the nanoparticles it is unable to enter the gel and appears solely in the well of the stacking gel. Before the last step of purification a faint band is observed at the correspondent size of the free thiolated antibody, corresponding to the small fraction of unreacted antibody (Figure S1, B, column 4) .
Conversely, after the last step of purification (Figure S1, B, column 5 ) no free antibody can be detected asserting for the purification procedure. (scale bar 50 nm). 
In vitro experiments
In vivo experiments
Bone tumor model:
BT474 breast cancer cells were harvested, counted with a Malassez cell counter and transferred into RPMI medium without serum before injection in NOD/SCID mice (8 week old, body weight =18-22 g). Mice were anesthetized with isoflurane (1-1.5% in air). After shaving the limb, the femur was exposed and a 0.6 mm hole was generated with a driller (Harvard Apparatus, Les Ulis, France). Mice were injected with 10 μL, containing one million tumor cells, into the intramedullary canal of the femur in the epiphysis region with Hamilton syringe. Bone wax was used to obturate the injection hole.
All experimental procedures were approved by the local institutional ethics committee (approval n° 33010001-A).
Mice were followed for several months, using MRI, in order to assess tumor progression ( Figure S3) . Presence of HER2 expression in newly formed tumor tissue in bone was confirmed ex vivo before nanoparticle administration (Figure S4) .
In vivo MRI:
Animal preparation for MRI:
Mice were anesthetized using isoflurane (1-1.5% in air). Gradient insert temperature was maintained at 37°C and a system for monitoring physiological parameters used to control respiration rate (SA Instruments, Inc., Stony Brook, NY, USA).
Biodistribution measurement:
For scanning the whole mouse in one shot, a mouse whole body coil was used. It was an eight-leg high-pass birdcage resonator with a resonator diameter of 28 mm and a resonator Keyhole reconstruction and image analysis were performed with homemade software developed on Igor Pro [37] .
MRI tumor progression monitoring:
MRI was performed in a vertical bore spectrometer at 9. x 83 x 83 μm 3 , receiver bandwidth: 52 kHz. The final 3D TrueFISP image was made from the combination of eight acquisitions sets. Each set was acquired with a specific difference in phase between consecutive radio frequency pulses. The differences in phase were ΔΦ= 180°, 0°, 90°, 270°, 45°, 135°, 225°, 315° [38] . TrueFISP image was made of the combination of four acquisitions sets. Each set was acquired with a specific difference in phase between consecutive radio frequency pulses. The differences in phase were ΔΦ= 180°, 0°, 90°, 270° [38] . Reconstructions were performed with Igor Pro data processing software (Wavemetrics, Lake Oswego, OR, USA). The final TrueFISP images were calculated as the square root of the sum-of-square of the four images.
The total acquisition time was 20 minutes.
A reference image was acquired with these parameters before nanoparticle intra venous bolus injection (100 μL).
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